Skip to main content
. 2008 Feb 26;98(5):875–880. doi: 10.1038/sj.bjc.6604263

Table 2. Recurrence (course and management) in patients with stage III and VI colon and rectal cancer during a 2-year follow-up strategy of conventional surveillance or additional PET-18FDG.

  Intention to Per protocol P
Total, N 130 125  
 FDG-PET 65 60
 Con. 65 65  
       
Recurrence, N 46 44  
 FDG-PET 25 23
 Con 21 21  
       
Time to recurrence (month) ±s.d.
 FDG-PET 12.0±4.9 12.1±3.7  
 Con 15.3±4.9 15.4±5 0.01
       
Time to therapy (month)±s.d.
 FDG-PET 15.5±5 14.8±4.1 0.09
 Con 17.5±6 17.5±6  
       
Biopsies and surgery, N (% over total) 27 (20.8) 27 (21.6)  
 PET-18FDG 15 (23) 15 (25)  
 Con 12 (18.5) 12 (18.5) 0.67
       
Surgery operation, N (% over recurrences) 17 (37) 17 (38.6)  
 PET-18FDG 15 (60) 15 (65)  
 Con 2 (9.5) 2 (9.5) <0.0001
       
R0 curative, N (% over recurrences) 12 (26) 12 (27.3)  
 PET-18FDG 10 (40) 10 (43.8)  
 Con 2 (9.5) 2 (9.5) <0.01
       
Death, N (% over recurrences)   9 (20.5)  
 FDG-PET 3 (13)  
 Con 6 (28.5) 0.33
       
Time to (months)
 FDG-PET 8.4, 21.3, 23.2  
 Con 9.1, 9.4, 10, 12, 13, 21.3  

Con=conventional, FDG-PET=18fluorodeoxyglucose positron emission tomography.